Engineering Better Outcomes: Mechanistic Innovations in CAR T and Bispecific Therapy

This talk will explore emerging strategies to optimize cellular and immune-based therapies across hematologic malignancies. Dr. Wendy Beguelin will examine the mechanistic underpinnings of CAR T-cell and bispecific antibody therapies, resistance pathways, toxicity management, and novel engineering approaches designed to improve durability, precision, and patient outcomes. Through evidence-based discussions and translational insights, participants will gain practical knowledge to inform treatment selection and integration of next-generation immunotherapies into clinical practice.